Recruiting Participants to Cancer Prevention Clinical Trials: Lessons From Successful Community Oncology Networks
Purpose/Objectives: To describe the organizational designs and task environments of community oncology networks with high accrual rates to cancer prevention clinical trials.
Design: Replicated case study design; structural contingency theory.
Setting: Local Community Clinical Oncology Programs (CCOPs) funded by the National Cancer Institute to test preventive and therapeutic interventions in community settings.
Sample: Primary sample: oncology professionals affiliated with four CCOPs ranking among the top 10 in earned cancer control accrual credits in fiscal years 1999-2003. Secondary sample: oncology professionals affiliated with three CCOPs ranking among the top 10 three to four times during the study period. A total of 63 people participated in the interviews.
Methods: Primary sample: on-site interviews with CCOP investigators, clinical research staff, and nononcology physicians. Secondary sample: telephone interviews with each CCOP's nurse administrator and at least one prevention research nurse.
Main Research Variables: Staffing patterns, organizational processes, recruitment strategies, and environmental characteristics.
Findings: All of the CCOPs employed dedicated prevention research staff. Recruitment through media publicity, mass mailings, or group information sessions worked best when prevention trials had flexible eligibility requirements and evaluated interventions with few health risks. Prevention trials evaluating agents with known toxicities in high-risk populations required more targeted recruitment through cancer screening programs, physician referral networks, and one-on-one discussions with protocol candidates.
Conclusions: High-performing CCOPs configured their structures, processes, and recruitment strategies to fit with accrual goals. They also benefited from stable and supportive task environments.
Implications for Nursing: Nurse-coordinated research networks have great potential to generate new knowledge about cancer prevention that can reduce cancer incidence and mortality significantly.
Jump to a section
References
Aventis Pharmaceuticals, Inc. (2004). Summary of HMO penetration by state. Retrieved September 3, 2005, from http://www.managedcaredigest.com/ShowReportAction.do?digest=28&ReportID=2713
Bailey, J.M., Bieniasz, M.E., Kmak, D., Brenner, D.E., & Ruffin, M.T. (2004). Recruitment and retention of economically underserved women to a cervical cancer prevention trial. Applied Nursing Research, 17, 55-60.
Barrett, R. (2002). A nurse's primer on recruiting participants for clinical trials. Oncology Nursing Forum, 29, 1091-1098.
Byers, T., Mouchawar, J., Marks, J., Cady, B., Lins, N., Swanson, G.M., et al. (1999). The American Cancer Society challenge goals. How far can cancer rates decline in the United States by the year 2015? Cancer, 86, 715-727.
Carpenter, W.R., Weiner, B.J., Kaluzny, A.D., Domino, M.E., & Lee, S.Y. (2006). The effects of managed care and competition on community-based clinical research. Medical Care, 44, 671-679.
Feigl, P., Patmont, C., Rodenbaugh, J., Smith, J., Glaefke, G., Allison, C., et al. (1987). Community cancer care evaluation final report: Vol. 5, integrated analysis (NCI contract N01-CN-35009). Seattle, WA: Fred Hutchinson Cancer Research Center, Statistical Analysis and Quality Control Center.
Fisher, B., Costantino, J.P., Wickerham, D.L., Redmond, C.K., Kavanah, M., Cronin, W.M., et al. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute, 90, 1371-1388.
Ford, L.G., Minasian, L.M., McCaskill-Stevens, W., Pisano, E.D., Sullivan, D., & Smith, R.A. (2003). Prevention and early detection clinical trials: Opportunities for primary care providers and their patients. CA: A Cancer Journal for Clinicians, 53, 82-101.
Galbraith, J.R. (1973). Designing complex organizations. Reading, MA: Addison-Wesley Publishing Company.
Galbraith, J.R. (1977). Organization design. Reading, MA: Addison-Wesley Publishing Company.
Hawk, E.T., Umar, A., & Viner, J.L. (2004). Colorectal cancer chemoprevention—An overview of the science. Gastroenterology, 126, 1423-1447.
Henry, R.A., & Strickland, O.J. (1994). Performance self-predictions: The impact of expectancy strength and incentives. Journal of Applied Social Psychology, 24, 1056-1069.
Jennings-Dozier, K., & Mahon, S.M. (2000). Introduction: Cancer prevention and early detection—From thought to revolution. Oncology Nursing Forum, 27(9, Suppl.), 3-4.
Kaluzny, A.D., Warnecke, R.B., Lacey, L.M., Morrissey, J.P., Gillings, D., & Ozer, H. (1993). Cancer prevention and control within the National Cancer Institute's clinical trials network: Lessons from the Community Clinical Oncology Program. Journal of the National Cancer Institute, 85, 1807-1811.
Katz, D., & Kahn, R.L. (1978). The social psychology of organizations (2nd ed.). New York: John Wiley and Sons.
Klabunde, C.N., Kaluzny, A.D., & Warnecke, R.B. (2000). Bringing cancer prevention and control protocols to the community. In A.D. Kaluzny & R.B. Warnecke (Eds.), Managing a health care alliance: Improving community cancer care (2nd ed., pp. 147-170). Frederick, MD: Beard Books.
Lippman, S.M., Goodman, P.J., Klein, E.A., Parnes, H.L., Thompson, I.M., Jr., Kristal, A.R., et al. (2005). Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute, 97, 94-102.
Lippman, S.M., & Hong, W.K. (2002). Cancer prevention science and practice. Cancer Research, 62, 5119-5125.
Lippman, S.M., & Levin, B. (2005). Cancer prevention: Strong science and real medicine. Journal of Clinical Oncology, 23, 249-253.
Locke, E.A., & Latham, G.P. (1990). A theory of goal setting and task performance. Englewood Cliffs, NJ: Prentice-Hall.
Loescher, L. (2004). Nursing roles in cancer prevention position statements. Seminars in Oncology Nursing, 20, 111-120.
McKinney, M.M., Warnecke, R.B., & Kaluzny, A.D. (2000). Integrating prevention and control protocols into a clinical trials network. In A.D. Kaluzny & R.B. Warnecke (Eds.), Managing a health care alliance: Improving community cancer care (2nd ed., pp. 131-145). Frederick, MD: Beard.
Nadler, D.A., & Tushman, M.L. (1982). A model for diagnosing organizational behavior: Applying the congruence perspective. In D.A. Nadler, M.L. Tushman, & N.G. Hatvany (Eds.), Managing organizations: Readings and cases (pp. 35-48). Boston: Little, Brown and Company.
National Cancer Institute. (2004). Decades of progress: 1983-2003 Community Clinical Oncology Program [Anniversary book]. Retrieved September 9, 2005, from http://www.cancer.gov/prevention/ccop20th
Oncology Nursing Society. (2001). Prevention and early detection of cancer in the United States. Retrieved October 4, 2005, from http://www.ons.org/publications/positions/PreventionDetection.shtml
Paskett, E.D., Katz, M.L., DeGraffinreid, C.R., & Tatum, C.M. (2003). Participation in cancer trials: Recruitment of underserved populations. Clinical Advances in Hematology and Oncology, 1, 607-613.
Ragin, C.C. (1999a). The distinctiveness of case-oriented research. Health Services Research, 34(5, Pt. 2), 1137-1151.
Ragin, C.C. (1999b). Using qualitative comparative analysis to study causal complexity. Health Services Research, 34(5, Pt. 2), 1225-1239.
Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., et al. (2003). The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349, 215-224.
Weiner, B.J., McKinney, M.M., & Carpenter, W.R. (2006). Adapting clinical trials networks to promote cancer prevention and control research. Cancer, 106, 180-187.
Wickerham, D.L. (2003). Tamoxifen's impact as a preventive agent in clinical practice and an update on the STAR trial. Recent Results in Cancer Research, 163, 87-95.
Yin, R.K. (1994). Case study research: Design and methods (2nd ed.). Thousand Oaks, CA: Sage Publications.